For investors looking for a dependable source of passive income, a systematic screening method is important. One useful technique focuses on finding companies that provide a good dividend now and also have the fundamental financial soundness to maintain and possibly raise those payments in the future. This method focuses on quality and longevity over pursuing the largest available yield, which can sometimes indicate company trouble. A good initial step is a filter that finds stocks with a high ChartMill Dividend Rating, along with satisfactory ratings for Profitability and Financial Health. This pairing aids in finding companies where the dividend is backed by reliable earnings and a firm balance sheet.
Johnson & Johnson (NYSE:JNJ), the worldwide healthcare leader, recently passed through such a screening filter. The company's basic profile, especially its dividend traits, makes it a strong option for investors concentrating on income and steadiness. According to its detailed fundamental analysis report, JNJ receives an overall rating of 6 out of 10, with high ratings in Profitability (8) and Dividend (7), while its Financial Health rating is a satisfactory 6. In a difficult market where both long and short-term trends for the S&P 500 are unfavorable, the protective quality and steady results of a company like JNJ can be especially attractive.
A Dividend Profile Founded on Dependability
For dividend investors, the record and longevity of payments are frequently more important than the basic yield. Johnson & Johnson is strong in these quality aspects, which create the foundation of a reliable income stock.
- Long History: JNJ has a very dependable dividend record. The company has both paid and raised its dividend for at least 10 straight years. This enduring dedication shows a culture focused on shareholders and a focus on returning capital through various economic periods.
- Consistent Increase: The dividend has risen at an average yearly rate of 7.68% over the last five years. This reliable increase assists income investors in offsetting inflation and raising their cash flow over time, a major benefit compared to fixed-income options.
- Maintainable Payout: The dividend's longevity is assessed through the payout ratio, which shows the share of earnings distributed as dividends. JNJ's payout ratio is 46.19%. While this is toward the upper end of a comfortable zone, it is considered workable. Critically, the analysis states that JNJ's dividend increase rate matches its earnings growth, indicating the present policy is maintainable without pressuring the company's finances.
Profitability: The Source Supporting the Dividend
A high dividend rating is only believable if supported by durable and consistent profits. This is why filtering for satisfactory profitability is a key part of the method, without earnings, dividends cannot be kept. Johnson & Johnson's Profitability Rating of 8 emphasizes its notable capacity to produce returns.
- Excellent Margins and Returns: The company functions with top-level efficiency. Its Profit Margin of 28.46% and Operating Margin of 27.78% are better than over 93% of similar companies in the pharmaceuticals industry. Also, its Return on Equity (32.87%) and Return on Invested Capital (14.37%) are in the highest group of the industry, showing very efficient use of shareholder money.
- Upward Direction: These notable margins are not fixed; they have displayed enhancement in recent years. This pattern of growing profitability supplies a firmer base for future dividend raises and strengthens the company's competitive position.
Financial Health: Evaluating the Balance Sheet
A satisfactory Health Rating is the last support of this screening method, making sure the company is not carrying too much debt and can endure economic declines without endangering its dividend. JNJ's Health Rating of 6 shows a varied but finally acceptable situation.
- Firm Solvency: The company's solvency, its capacity to meet long-term responsibilities, is solid. An Altman-Z score of 5.10 shows a very small near-term chance of financial difficulty. Its Debt to Free Cash Flow ratio of 2.43 is very good, meaning it would need just over two years of present cash flow to repay all debt, a ratio that is better than 92% of industry peers.
- Liquidity Factors: The report notes some points about short-term liquidity, with Current and Quick ratios that are lower than many rivals. However, the analysis usefully explains this by stating that given JNJ's exceptional solvency and profitability, these ratios do not necessarily point to immediate liquidity problems but should be viewed within the details of its big, global business activities.
Valuation and Growth Setting
While the main attention is on dividend longevity, valuation and growth outlook give important setting. JNJ's valuation is viewed as reasonable compared to both the market and its industry. Its P/E ratio is less than that of the average S&P 500 company and much less than the average for its pharmaceutical peers. Growth is anticipated to be stable, with analysts predicting EPS growth of about 8.75% yearly, which should aid continued dividend growth.
For investors applying a systematic screen to locate good dividend payers, Johnson & Johnson serves as a leading example of the method's result. It joins a dependable and increasing dividend, fueled by notable profitability, with a fundamentally healthy financial setup. It highlights the idea that in dividend investing, the quality and longevity of the payment frequently matter more than a seemingly high yield.
Interested in examining other stocks that meet this quality dividend filter? You can see the complete list and adjust the filters yourself using the Best Dividend Stocks screener.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. The analysis is based on current data and past performance, which is not indicative of future results. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.